Irsogladine maleate and rabeprazole in non-erosive reflux disease: A double-blind, placebo-controlled study

Figure 1 Total Frequency Scale for the Symptoms of Gastroesophageal reflux disease scores for groups I and P before and after four weeks of treatment. Values are expressed as the mean ± SD. FSSG: Frequency Scale for the Symptoms of Gastroesophageal reflux disease; NS: Not significant.

Figure 2 Changes in the Frequency Scale for the Symptoms of Gastroesophageal reflux disease scores for groups I and P after four weeks of treatment. Values are expressed as the mean ± standard deviations. Significant differences were found between the groups. ^aP = 0.03 and ^bP = 0.01. FSSG: Frequency Scale for the Symptoms of Gastroesophageal reflux disease.

Figure 3 Comparisons of the total Frequency Scale for the Symptoms of Gastroesophageal reflux disease scores between the study groups in relation to the non-erosive reflux disease grades N and M after four weeks of treatment. Values are expressed as the mean ± SD. FSSG: Frequency Scale for the Symptoms of Gastroesophageal reflux disease; NS: Not significant; NERD: Non-erosive reflux disease.

Figure 4 Quality of life assessment of patients in groups I and P before and after treatment using the Short Form-36 questionnaire. PF: Physical functioning; RP: Role limitation-physical; BP: bodily pain; GH: General health; VT: Vitality; SF: Social functioning; RE: Role limitation-emotional; MH: Mental health; NS: Not significant.

Figure 5 Quality of life assessment of patients in groups I and P before and after treatment using the Short Form-36 questionnaire for non-erosive reflux disease grades N and M. NERD: Non-erosive reflux disease; PF: Physical functioning; RP: Role limitation-physical; BP: bodily pain; GH: General health; VT: Vitality; SF: Social functioning; RE: Role limitation-emotional; MH: Mental health; NS: Not significant.